by Raynovich Rod | Sep 19, 2014 | Macro
Alibaba Should Open by 12 N EDT at $92.70, well above $68 IPO Price Price Discovery Underway with Trades moving toward $100 but now selling off to $93 up 36%. Alibaba (BABA) group may be sucking up a lot of cash from NASDAQ trades even with a option expiration. Money...
by Raynovich Rod | Sep 5, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Update-1 …Market Continues Sell-Off With QQQs Treading Water in September Follow Technicals on FBT and QQQ. The Federal Reserve continues to be the main concern of investors as the probability of a rate hike looms greater and sooner. Policy officials will meet...
by Raynovich Rod | Aug 22, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Life Science ETF's and Mutual Funds
Large Caps Rule Macro and Seasonal Risks Create a Choppy Market The August biotech rally has taken us to the midpoint of the February top and May bottom and is faltering. Look at the XBI SPDR S&P biotech ETF (XBI), a proxy for momentum and smaller cap trading, up...
by Raynovich Rod | Jul 22, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update 7/23 Biogen Idec (BIIB) Soars 11% on Earnings EPS at $3.49 vs est $2.83; Sales of MS drugs were $2.42B vs $1.72B last year. Our large cap portfolio is now up 15% YTD with less risk than mid and small caps. One analyst thinks PBYI will be acquired but watch out...
by Raynovich Rod | Jun 4, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Clinical Diagnostic Stocks Were Hit By Bio-Bubble or Revenue Miss Potential upside in EXAS, NSTG and NEOG all are Rayno Dx and Tools picks. With “momentum trading” days over for now, revenue growth is the focus. Companies with disappointing Q1 revenues:...
by Raynovich Rod | May 14, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Life Science ETF's and Mutual Funds
Update May 30-Fidelity Select Biotech (FBIOX) Fund is lagging Top ETFs FBT and IBB Compared to 2013 when FIDO beat the ETFs it is lagging post February bubble and YTD. It would be difficult to analyze why this happened but my guess is that: FIDO went chasing...
by Raynovich Rod | Apr 21, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Have A Strong Day-April 15 Bottom Holding Rayno Life Science Portfolios Stick with larger caps through earnings: ABBV, AMGN, ALKS, BIIB, GILD. MOMO mid cap stocks coming back today: INCY MDVN PBYI plus many others. Losers- Cepheid (CPHD and...
by Raynovich Rod | Apr 11, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Top Ten Reasons For Biotech Correction NASDAQ at 4022,IBB at 221 A Sentiment Driven Market We have been writing about the bull market in biotech stocks since its inception in March 2009 when quality companies were advancing their pipelines and new products in...
by Raynovich Rod | Mar 13, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools, Life Science ETF's and Mutual Funds
March 17 Update -GREEN DAY with Geopolitical risk on back burner As of 11.38a EDT Industrials lead up 1%, healthcare up 0.8%, IBB up 1.33% Biopharmaceuticals stocks were strong with Rayno large cap picks: Alexion (ALXN $117) up 1.45%, Amgen (AMGN $125) up 1.9%,...
by Raynovich Rod | Jan 20, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
2014 J.P.Morgan Healthcare Conference Update #4-Rayno Biopharmaceutical Picks Biotechnology started off with a roar and major indices were up 10% or more. Much of it can be attributed to the excitement and anticipation of the JPMorgan Conference with 10,000 attendees...
